UnitedHealth Group has released its 2025 financial outlook, falling short of Wall Street’s projections. The company expects adjusted earnings of at least $16 per share and revenue between $445.5 billion and $448 billion, compared to analyst expectations of $20.91 per share in earnings and $449.16 billion in revenue. This guidance reflects a continuation of rising medical costs and the removal of roughly $1 billion in projected gains from now-abandoned portfolio actions.
The insurer is navigating persistent pressure within its Medicare Advantage plans, where delayed procedures post-Covid—such as joint and hip replacements—are now resurging. The company cited underestimating the growing medical demand when setting 2025 plans and acknowledged that current plan structures did not adequately anticipate cost increases. As a result, UnitedHealthcare’s medical care ratio rose to 89.4% in the second quarter, up from 85.1% the previous year, indicating rising medical payouts in proportion to collected premiums.
Quarterly performance further underscores the strain. Adjusted earnings per share came in at $4.08 versus an expected $4.48, while revenue reached $111.62 billion, exceeding estimates due to strong growth from both UnitedHealthcare and Optum. UnitedHealthcare recorded $86.1 billion in revenue, a 17% year-over-year increase, though Optum Health saw a 7% decline. Conversely, Optum Rx delivered a 19% rise in revenue, reaching $38.46 billion.
Despite the revenue gains, the company faces ongoing regulatory and public pressure. It is currently complying with federal investigations into its Medicare billing practices. Leadership noted intensified efforts to enhance internal oversight and reduce consumer cost burdens, using audits and AI-driven policy tools. Independent external reviews are underway, with findings expected by the fourth quarter.
This marks the first earnings cycle under new CEO Stephen Hemsley, who addressed investor concerns by admitting to past pricing and operational missteps. He emphasized transparency and annual expert reviews of core functions such as care management and pharmaceutical services.
UnitedHealth is striving to rebound from a tumultuous 2024, which included a major cyberattack and high-profile internal turmoil. As shares have fallen over 44% year-to-date, restoring investor confidence is now central to the company’s strategic trajectory.
READ MORE: